Lenvima 4 MG Daily Dose and RPL syndrome
Result of checking the interaction of drug Lenvima 4 MG Daily Dose and disease RPL syndrome for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of lenvatinib may cause reversible posterior leukoencephalopathy syndrome (RPLS). Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. Confirm the diagnosis of RPLS with MRI and if positive, withhold therapy for RPLS until fully resolved. Upon resolution, resume at a reduced dose or discontinue treatment depending on the severity and persistence of neurologic symptoms and administer appropriate treatment as clinically indicated.
Generic Name: lenvatinib
Brand Name: Lenvima, Lenvima 8 mg daily-dose, Lenvima 20 mg daily-dose, Lenvima 12 mg daily-dose
Synonyms: Lenvima